Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial
Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
BTC
ETH
USDT
XRP
USDC
SOL
TRX
FIGR_HELOC
DOGE
WBT
USDS
HYPE
LEO
ADA
JPMorgan beat earnings expectations amid record market revenue, but a downbeat outlook for net interest income hurt the stock.
Most popular articles this week
Latest news from global stock markets, tech giants, and financial sectors
Browse ArticlesBitcoin, Ethereum, altcoins, DeFi, NFTs, and blockchain technology
Browse ArticlesGold, silver, oil, natural gas, and other precious commodities
Browse Articles
Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial
The home, inspired by Kubrick's 2001 movie "Space Odyssey" is located in a highly sought-after neighborhood of Hollywood Hills, but has been on the market...
Novo Nordisk shares plunge after obesity drug falls short of rival in trial
The company is studying its approved drug for many other indications.
Michael Saylor Hints at Strategy's 100th Bitcoin Purchase The post Michael Saylor Hints at Strategy's 100th Bitcoin Purchase Milestone appeared first on Cr...
U.S. stock-index futures declined Sunday, as investors grappled with the implications of Friday's Supreme Court ruling that overturned most of President Do...
The company might bend, but it won't break.
Bitcoin past performance gave 88% odds of higher prices by early 2027, the latest in a series of new bullish BTC price predictions.
Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug
Deutsche Bank cuts Telecom Italia and savings shares after 40% rally since Oct
Old Dominion's volumes are still sliding, but that hasn't stopped the stock from rallying.
"My son is smart - he really is - but he was in love."